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Endocrine Disorders: Principles of Management 
Capsaicin: A Therapeutic Option for Painful Diabetic Neuropathy 
Karen M. Basha, BSN, RN, CDE,* and Fred W. Whitehouse, MD' 
Fifteen patients with diabetes mellitus who had painful diabetic neuropalhy (PDN) were enrolled in a 
double-blind .study to test the .safety and efficacy of capsaicin 0,075% (Ax.sain. Genderm. Northbrook, 
IL). Twelve of the 15 patients completed the eight-week slutly. Nine trf the 12 patients reported 
symptomatic relief: trf these nine, five used the drug and four used Ihe vehicle. The three patients who 
reported no relief trf symptoms appUed the vehicle. Capsaicin is potentially effective when burning 
pain is a major sympttmi of PDN. The side effects trf capsaicin were limited and minimal. This agent 
should he considered hy clinicians for ireatmeni trf PDN. (Henry Ford Hosp Med J 1991:39:138-40) 
D iabetes mellitus (DM) affects more tiian 12 million people in the United States and its complications are the third 
leading cause of death today. All individuals with DM are sus-
ceptible lo the numerous complications of this disease. 
The macrovascular and microvascular complications of DM 
may lead to progressive end-organ involvement, the most pain-
ful of which is neuropathy. Clinical manifestations of painful 
diabetic neuropathy (PDN) include .severe burning ofthe low-
er limbs and feet with nocturnal intensification (oflen occur-
ring in a stocking-glove distribution), paresthesia, intermittent 
sharp or stabbing pains, anorexia, weight loss, and depression 
(1) . Of those with either long-.standing insulin-dependent diabe-
tes mellitus (IDDM) or noninsulin-dependent diabetes mellitus 
(NIDDM), 50%. will be affected by some form of neuropalhy 
(2) . 
Treatment of PDN includes biochemical control of the dia-
betic slale and appropriate pharmacologic therapy for symptom-
atic reliefi A variety of pharmacologic strategies are available 
including oral medications, such as nonopiate anodynes, tricy-
clic antidepressants, phenytoin, and vitamin B (use of some of 
these may be limited by systemic side effects), and local physio-
therapeutics, such as transepidural neural stimulation ("TENS"). 
Aldose reductase inhibitors are currently being studied, but no 
consensus yet exists on their efficacy and safety. 
Capsaicin (Axsain, Genderm, Northbrook, IL), a recently mar-
keted topical agent, has been used with some success in post-
herpefic neuralgia, post-mastectomy pain syndrome, and PDN. 
We participated in a mulficenter Capsaicin Study Group and re-
port our experience with this new agent in the treatment of PDN. 
shade family (Solanaceae). It is the chemical substance that 
makes hot peppers "hot." These plants were introduced in the 
15th century in Europe where they were used as a food or condi-
ment; they were also thought lo have several medicinal proper-
ties. Cap.saicin has also played a role in folk medicine, with its 
medicinal uses dating back to the 19th century. In recent years, 
this substance has been available in low concentrations and used 
in .several over-the-counter preparations for arthritis (3). 
As a topical cream, capsaicin is marketed in two strengths. 
0.025% and 0.075%. The lower strength of capsaicin was ini-
tially advised for patients with post-herpetic neuralgia. Use of 
capsaicin, 0.075%, has recently been studied in clinical trials for 
the treatment of post-mastectomy pain syndrome and PDN. Its 
side effects include burning, slinging, and erythema at the site of 
application (which usually diminishes with repeated use), dry 
skin, and nasal inhalation irritant reactions. Capsaicin is thought 
to deplete substance P, a pain-modulating neurotransmitter, at 
the nerve terminals. Initial applications sensitize the nerve fiber 
membrane to release substance P, and continued use desensi-
tizes the membrane which subsequently reduces local concen-
trations of substance P. Hence, the area of capsaicin application 
becomes less sensitive to pain. This decrease in pain is tempo-
rary but is sustained with repeated use of capsaicin (4). Studies 
suggest that when capsaicin is di.scontinued the deplefion of 
substance P slops and symptoms retum (5). 
Pharmacology of Capsaicin 
Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is an 
active ingredient found in many botanical species of the night-
Submitted for publication: February 2,5, 1991, 
Accepled for publication: May 20, 1991, 
•Division of Endocrinology and Metabolism, Henry Ford Hospilal, 
Address con-espondence lo Ms, Basha, Division of Endocrinology and Melabolisni, 
Henry Ford Hospilal, 2799 W Grand Blvd, Detroit, Ml 48202, 
138 Henry Ford Hosp Med J—Vol 39, No 2, 199 i Capsaicin for PDN—Basha & Whitehou,se 
Body Area A f f e c t e d : 
( f o r Fteripheral Polynemx^sathy) 
uxxncm OF NEDRALGIA 
Dermatome Affected: 
(for Radiculcpathy) 
PAIN SEVERITY 
None(O) 
1 1 
S l i g h t ( l ) 
t 1 
Moderate (2) 
[ ) 
Severe(3) 
[ 1 
Very Severie(4) 
1 ] 
Fig 1—Dermatome chart used to record location of pain. 
Multicenter Capsaicin Study Group 
A total of 277 diabetic patients (136 IDDM and 141 NIDDM) 
with PDN were randomized to an eight-week, double-blind, 
placebo-controlled, multicenter clinical trial using eilher capsa-
icin or vehicle (placebo) to evaluate the clinical safety and effi-
cacy of topically applied capsaicin cream (0,075%). Patients in-
cluded 139 men and 138 women with a mean age of 60 years 
(range 27 to 81 years). The 12 medical centers across the United 
States participating in the study each randomized a mean of 20 
patients (range 9 to 54) inlo one ofthe two groups. 
The Henry Ford Hospital group enrolled 15 patients (9 fe-
male, 6 male) whose ages ranged from 48 to 79 years (mean 64 
years). Eight patients had IDDM; seven patients had NIDDM. 
The duration of DM ranged from 6 months to 24 years (mean 
12 years). Twelve of the patients had peripheral polyneuropathy 
and three had radiculopathy. The duration of the symptomatic 
neuralgia ranged from 2 months lo 15 years (mean 4 years). 
Inclusion criteria included: I) individuals wilh IDDM or 
NIDDM belween ages 18 to 85 years; 2) a fasting blood glucose 
< 180 mg/dL or a glycosylated hemoglobin < 11%; 3) presence 
of either clinical peripheral polyneuropathy or radiculopathy, 
characterized by local pain and paresthesia confirmed by find-
ings on electromyogram (EMG); 4) pain interfering with daily 
activities and/or sleep at least some of the time; 5) other topical 
medications applied to the affected areas discontinued at least 
seven days prior to study entry; 6) all oral medications for pain 
associated with neuropathy continued but without change in 
dosage or frequency of administration; 7) medication prescribed 
for indications other than pain could be initiated provided their 
use did not interfere with the evaluation of the study drug. In-
formed conseni was obtained from all participanls in the study. 
Exclusion criteria included; I) females who were pregnant or 
lactating; 2) patients who had open lesions on the affected skin 
area; 3) individuals with a serious medical or psychiatric dis-
ease. 
Before randomization at a pretreatment visit, the history was 
obtained and directed neurological examination performed. 
PATIENT INSTRUCTIONS 
1, Apply the medication cream to painful areas of your skin FOUR TIMES A DAY lor the 
duration o l the sludy. Even if pain slops, continue medication until your iast visit to 
the clinic, 
ALWAYS WASH YOUR HANDS AFTER APPLICATION OF THE CREAIVl. AVOID 
CONTACT WiTH YOUR EYES AND WiTH ANY OPEN WOUNDS OR iRRITATED 
SKiN WHEN APPLYING THE CREAIVl, KEEP OUT OF REACH OF CHILDREN. 
2, When the drug is applied to normal skin, there may be mild to moderale d iscomfor l 
and burning or sl inging sensations, especiaiiy during the f irsl v^eek of Irealmenl. 
Repealed appl ical ion usually resulls in el imination or marked decrease of this discom-
fort. If you so choose, you may take two |2) tablets of aspirin or acetaminophen (e,g., 
Tylenoi, Anacin-3, Datril), every four hours, for relief of the discomfort. However, if 
such discomfort is too disUessing, you should call your doctor, and bolh of you will 
decide whether you should continue using lhe study medication. 
3, Bring all used lubes of medication with you lo your next scheduled visit. 
4, Your doctor may consider making changes in your pain medications. If 31 any l ime, 
you make a change in lhe amounl or lype ot medical ion you are taking, notify your 
doctor, 
5, Your doctor will schedule the clinic visits for you as tol iows: 
— 2 weeks after your ini l ial visit of the open label study 
— 8 weeks afler your ini l lai visit 
— then every 8 weeks, up to a total of one year on the sludy 
Please contaci your doctor at any time during the sludy if your pain worsens. 
NOTE: Your doctor will also make a telephone fo l low-up 
call at 4 and 6 weeks after your initial visit. 
6 Once you finish the sludy, your doctor will call you periodically lo assess wheiher your 
pain has changed after discontinuation of the study medication. 
Fig 2—Patient instructiems frn- the application erf study medica-
tion to the affected areas. 
Nerve conduction was studied in patients who had not had the 
test in the previous six months. EMG, used at the onset of the 
study to confirm the diagnosis of PDN, was not repeated. The 
anatomical distribution of the pain was recorded on a derma-
tome chart (Fig 1). 
Patients were randomly assigned into one of two study groups 
ulilizing eilher capsaicin or a vehicle and were instructed lo ap-
ply the cream to the affected area four times daily. Each patient 
was informed ofthe possible side effects of capsaicin and given 
an instruction sheet to follow (Fig 2). Instructions were reviewed 
and questions and concerns regarding the protocol were dis-
cussed with the patient prior to leaving the clinic. 
The side effects of capsaicin included mild to moderate bum-
ing or stinging when applied to the affected area. If side effects 
occurred, patients were instructed to lake two tablets of aspirin 
or acetaminophen every four hours. If symptoms were severe, 
patients were instructed to contact the clinic promptly lo deter-
mine ifthe study drug should be discontinued. Each patient was 
also instructed to avoid contact with their eyes and mucous 
membranes when applying the cream and to wash their hands 
after each use. Al baseline and at weeks 2, 4, 6, and 8, pain was 
assessed by the patient and nurse coordinator using three stan-
dard pain scales; physician global evaluation (PGE), visual ana-
logue scale for pain intensity (VAS-P), and visual analogue scale 
for pain relief (VAS-R). The PGE was completed by the nurse 
coordinator and physician with input from the patient to assess 
changes in pain severity compared to baseline. The other two 
scales were completed by the patient. Patients were instructed to 
complete these questionnaires based on the time or times of the 
day the pain was most intense. 
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Fig 3—Schema frn- double-blind capsaicin studv. 
Results 
Ofthe 15 patients enrolled in the Henry Ford Hospital group, 
seven used capsaicin and eight u.sed the vehicle cream during 
the study period. Twelve patients completed the trial; of the 
three patients who dropped out, two did so because of severe 
burning (1 capsaicin, I vehicle) and one because of treatment 
failure (capsaicin). Nine patients reported moderate lo complete 
relief of pain during the trial (5 capsaicin. 4 vehicle), and three 
patients reported no relief (all vehicle) (Fig 3). 
Discussion 
The results of the multicenter Capsaicin Study Group dem-
onstrate that capsaicin offers symptomatic relief in the treatment 
of PDN and radiculopathy (6). These findings were based on the 
analyses of the efficacy parameters (i.e., PGE, VAS-P, VAS-R). 
Of the 277 patients randomized nationally, 138 received capsa-
icin and 139 received vehicle. Based on the final visit analyses 
of standard pain scales, 69.5% of the patients in the capsaicin 
group and 53.4% of the patients in the vehicle group reporied 
improvement in pain (PGE) (P < 0.012). A total of 38.1 % of the 
patients in the capsaicin group and 27.1% in the vehicle group 
reported a decrease in pain intensity (VAS-P) (P < 0.037). Fi-
nally. 58.4% of the cap.saicin group and 45.3% of the vehicle 
group reported they had a relief of pain (VAS-R) (P < 0.004). All 
of these are significanl at the 5% level (6). 
In lighl of the overall findings of the multicenter group, we 
feel that capsaicin is worthy of consideration in the treatment of 
PDN. The placebo respon.se, not uncommon in pain studies, can 
be attributed lo the following factors; scheduled visits to talk 
with the patient regarding pain, patient response to the placebo 
effeci, and rubbing the area .skin with lanolin ointment which in-
creases the local blood supply and is soothing to the skin. 
Capsaicin is indicated in patients whose primary complaint 
from neuropalhy is pain. Most patients whose symptoms im-
proved with capsaicin reported buming pain as a primary com-
plaint. The drug has not yet been studied in patients whose pri-
mary complaint is numbness or dysesthesia. A few patients with 
localized sensory mononeuropathy (intercostal and truncal neu-
ropathy or meralgia paresthetica) may also benefit from its use. 
The goal of therapy, symptomatic relief, should occur two to 
six weeks after beginning therapy. Therapy is instituted with 
0.025% capsaicin applied to the affected area four times daily. 
Ifno response is achieved, we advise the more concentrated 
form of 0.075% four times daily. Once relief is obtained, fre-
quency of use can be adjusted to maintain symptom control ac-
cording to individual need. 
The advantages of capsaicin are; 1) application directly to the 
affected area, 2) no systemic effects, and 3) diminished local 
side effects with repeated use of the cream. Disadvantages in-
clude: 1) local side effects at the site ofapplication, which, if 
.severe, may require discontinuation of the medication; 2) high 
costof treatment ($53 to $55 for a 45-gram tube of capsaicin at 
the 0.075% strength and an average of $35 for a 45-gram tube 
at the 0.025% strength, with each tube permitting two to three 
weeks of therapy when used as advised); and 3) possible use 
without medical advice as patients may obtain it over-the-coun-
ter without a prescription. If local burning pain is a primary 
complaint of patients with diabetic neuropathy, the use of capsa-
icin merits a trial. Of course, this medication is not used in the 
presence of skin ulcers or infection. Although the results in our 
small sample of patients are not decisive, the multicenter report 
persuades us that the agent has therapeutic benefit. The fre-
quency of relief by vehicle cream (in our experience as well as 
in the multicenter study) emphasizes the need for double-blind 
studies when assessing clinical effectiveness. 
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